Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04830397 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
A Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT04830397 is a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma that has completed, run by Qlaris Bio. The registered enrollment target is 84 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04830397, a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Timolol Maleate
- DRUG QLS-101
Study Locations (1)
Georgia
- Dixon Eye Care - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04830397
The ClinicalTrials.gov registry entry for NCT04830397 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (70% lower). The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Timolol Maleate is the first listed.
NCT04830397 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04830397 about?
NCT04830397 is a clinical study titled "Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).". Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
What is the current status of trial NCT04830397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2021-03-31. Estimated completion is 2022-02-17.
What conditions does trial NCT04830397 study?
This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma.
What interventions are being tested in trial NCT04830397?
The interventions under investigation include: Timolol Maleate (DRUG), QLS-101 (DRUG).
Who is sponsoring clinical trial NCT04830397?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04830397 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.